Q-omics provides the consensus-scored ZNF781 profile across patient tissues and cancer cell-line models. ZNF781 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF781 is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, ZNF781 RNA expression shows 20,019 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUAD, THCA, and PDAC as cancer lineages where ZNF781 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF781 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF781 survival associations across molecular data types. ZNF781 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF781 RNA expression–survival associations across cancer types. High ZNF781 expression shows unfavorable associations in OV, but favorable associations in LUAD, UCS, PAAD, UVM and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF781 RNA expression.
This table summarizes ZNF781 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF781. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF781 shows lower tumor expression in THCA, KICH, LUSC, KIRP, COAD and LUAD. The THCA box plot shows higher ZNF781 RNA expression in normal versus tumor tissue (log2 FC = −1.577, t-test p < 0.001).
This table shows molecular features associated with ZNF781 in patient tissues and cancer cell lines. In patient samples, ZNF781 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF781 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
